Table of Contents

Bortezomib-rituximab results in improved PFS and response rates vs. Rituximab, and quality of response is associated with improved outcomes, in patients with relapsed FL

NE Oncology Issue - August 2011 Coiffier B, et al. EHA 2011: Abstract 0361 Background Outcomes in patients with follicular lymphoma (FL) have improved in recent years because of the introduction of new therapies, and the quality of response to first-line therapy is...

Download Journal


Canadian Perspectives

Bernard Lemieux, MD, FRCPC
Dr. Bernard Lemieux is a Medical Oncologist in the Department of Hematology at the Centre Hospitalier de l’Université de Montreal (CHUM) and Hôpital NotreDame. He received his medical degree from the University of Montreal in 1996 and completed his medical specialty in hematology and medical oncology, followed by a clinical fellowship in lymphoproliferative disorders from 2002–2003 at the Centre Hospitalier Lyon-sud, France. He is past president of the Quebec HematoOncology Association (AMHOQ). Currently, he is Medical Director of the Hematologic Disorders Team and the Lymphoproliferative Disease Clinic and co-director of the Medical Oncology Clinical Research Unit (URCOH) at CHUM.

Laurie H. Sehn, MD, MPH
Dr. Laurie H. Sehn is a Clinical Assistant Professor at the BC Cancer Agency and the University of British Columbia in Vancouver. She has been a medical oncologist and clinical investigator with the Lymphoma Tumour Group since 1998. Dr. Sehn has served on the Board of Directors of Lymphoma Foundation Canada (LFC) since 2002 and is currently Director of Research Fellowships for the LFC. Dr. Sehn’s research interests include all of the lymphoid cancers, with particular interest in the biology and treatment of large-cell lymphoma, the application of new imaging techniques such as PET scanning to lymphoma management, and innovative new approaches to treatment.

Douglas A. Stewart, BMSc, MD, FRCPC
Dr. Douglas A. Stewart is currently a professor in the Departments of Oncology and Medicine, and Chief of the Division of Hematology and Hematological Malignancies at the University of Calgary. Since July 1994, he has been practising medical oncology at the Tom Baker Cancer Centre in Calgary, where he is a member of the Breast Cancer and Hematology Tumour Groups, Leader of the Hematology/Blood and Marrow Transplant Program, and Provincial Leader of the Hematology Tumour Team for the Alberta Health Services Cancer Care Program. His research interests focus on clinical trials involving hematological malignancies and hematopoietic stem cell transplantation. Dr. Stewart has authored over 80 peer-reviewed manuscripts and over 120 abstracts.

Investigator Commentaries

Martin Dreyling, MD, PhD
Dr. Martin Dreyling is an attending physician and associate professor in the Medical Department of the University of Munich, Grosshadern, Germany. His primary interests include the molecular biology and clinical care of lymphoma. Dr. Dreyling’s research activities relate to the molecular basis of malignant transformation, cell cycle dysregulation in mantle cell lymphoma (MCL), secondary genetic alterations and biological prognostic factors in malignant lymphoma, and innovative therapeutic approaches in indolent lymphoma. He is actively involved in a number of national and European study groups, and is currently the Coordinator of the European MCL Network. Dr. Dreyling has co-authored over 300 scientific papers, book chapters, and published abstracts in international peer-reviewed journals.

Liat Vidal, MD
Dr. Liat Vidal is a senior physician at the Institute of Hematology in the Beilinson Hospital, Rabin Medical Center in Israel. She received her medical degree from the Hebrew University in Jerusalem in 1998 and completed her residency in internal medicine at the Beilinson Hospital, Rabin Medical Center in 2004. From 2006 to 2007 she worked as a physician in hematology/oncology at the Hasharon Hospital, Rabin Medical Center. Dr. Vidal has a Master’s degree in epidemiology and her research interests include evidence-based medicine, systematic review, and meta-analysis.